Alnylam Pharma (ALNY) AI Stock Analysis

Compare

1,318 Followers

Top Page

Alnylam Pharma

(NASDAQ:ALNY)

Select Model

Neutral 60 (OpenAI - 4o)

Rating:60Neutral

Price Target:

$479.00

▲(5.93% Upside)

Alnylam Pharma's overall stock score is primarily influenced by its strong earnings call performance, which highlights significant revenue growth and positive future guidance. However, financial performance remains a concern due to high leverage and negative profitability, which are significant risks. Technical analysis indicates strong momentum but warns of potential overbought conditions. Valuation metrics are weak due to negative earnings and lack of dividends.

Positive Factors

Revenue Growth

Strong revenue growth driven by successful product launches indicates robust market demand and enhances long-term financial stability.

Product Launch Success

The successful launch of AMVUTTRA demonstrates Alnylam's effective commercialization strategy, supporting sustained revenue growth and market expansion.

Global Expansion

Regulatory approvals in key markets enhance Alnylam's global reach, allowing access to a larger patient base and supporting long-term growth.

Negative Factors

High Leverage

High leverage can strain financial resources, limiting flexibility and increasing risk, potentially impacting long-term financial health.

Negative Profitability

Persistent negative profitability despite efficient production indicates challenges in cost management, affecting long-term financial sustainability.

Decreased Collaboration Revenue

Reduced collaboration revenue may limit funding for R&D and strategic initiatives, impacting future growth and innovation potential.

Alnylam Pharma (ALNY) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$59.21B

Dividend YieldN/A

Average Volume (3M)1.18M

Price to Earnings (P/E)―

Beta (1Y)1.09

Revenue Growth5.01%

EPS Growth-330.09%

CountryUS

Employees2,230

SectorHealthcare

Sector Strength45

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.51

Shares Outstanding131,079,010

10 Day Avg. Volume1,204,762

30 Day Avg. Volume1,182,691

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.72

Enterprise Value/Revenue17.25

Enterprise Value/Gross Profit20.63

Enterprise Value/Ebitda-248.52

Forecast

1Y Price Target

$460.63

Price Target Upside1.87% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering28

Alnylam Pharma Business Overview & Revenue Model

Company DescriptionAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies based on RNA interference (RNAi). Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is a leader in the RNAi therapeutics sector, aiming to treat a range of diseases by silencing specific genes. The company's core products include Onpattro (patisiran), which is approved for the treatment of hereditary transthyretin-mediated amyloidosis, and several other investigational therapies targeting various genetic disorders and conditions.

How the Company Makes MoneyAlnylam Pharmaceuticals generates revenue primarily through the sale of its approved therapies, most notably Onpattro. The company also earns income through collaborations and partnerships with other pharmaceutical companies, which may include upfront payments, milestone payments based on development progress, and royalties on product sales. Notable partnerships with companies like Sanofi and Regeneron have further enhanced its revenue streams, allowing for shared development costs and increased market reach. Additionally, Alnylam may receive government grants and funding for research projects, contributing to its earnings.

Alnylam Pharma Key Performance Indicators (KPIs)

Any

Revenue by Segment

Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and indicating strategic focus areas.

Chart InsightsAlnylam Pharma's revenue growth is primarily driven by the robust performance of Amvuttra, which has seen significant uptake since its launch, contributing to a 77% increase in the TTR franchise. The recent earnings call highlighted a strong financial outlook, with increased revenue guidance for 2025, reflecting confidence in sustained growth across the portfolio. Despite decreased collaboration revenue and increased operating expenses, the company's strategic focus on international expansion and successful product launches, particularly Amvuttra, are key drivers of its positive financial trajectory.

Data provided by:

Main Street Data

Alnylam Pharma Earnings Call Summary

Earnings Call Date:Jul 31, 2025

(Q2-2025)

% Change Since: |

Next Earnings Date:Oct 23, 2025

Earnings Call Sentiment Positive

The earnings call for Alnylam Q2 2025 highlighted strong commercial performance and successful product launches, particularly for AMVUTTRA in ATTR-CM, leading to an upgraded financial outlook. Despite some decreases in collaboration revenue and product sales margins, the overall sentiment remains highly positive due to the robust growth and positive future guidance.

Q2-2025 Updates

Positive Updates

Exceptional Q2 Commercial Performance

Alnylam's Q2 commercial portfolio delivered $672 million in net product revenues, representing 64% year-over-year and 43% quarter-over-quarter growth. The U.S. TTR performance was the major driver of growth, particularly due to the ATTR-CM launch for AMVUTTRA.

Successful Launch of AMVUTTRA in ATTR-CM

In the first full quarter of the ATTR-CM launch, Alnylam reported $544 million in global net TTR product revenues, a 77% increase compared to Q2 2024. Approximately 1,400 cardiomyopathy patients were receiving AMVUTTRA, contributing an estimated $150 million in revenue.

Upgraded Financial Guidance

Alnylam increased its 2025 net product revenue guidance from a range of $2.05 billion to $2.25 billion to a revised range of $2.65 billion to $2.8 billion, representing a 27% increase at the midpoint.

FDA Fast Track Designation for Nucresiran

The FDA granted Fast Track Designation to nucresiran for ATTR-CM, enabling a more streamlined review process.

Global Expansion

AMVUTTRA has regulatory approvals in Europe, Japan, and Brazil, with launches in Germany and Japan unlocking access to more patients worldwide.

Negative Updates

Decreased Collaboration Revenue

Collaboration revenue for the quarter was $61 million, representing a $166 million decrease compared to last year, primarily due to the modification of the cemdisiran collaboration agreement with Regeneron.

Decreased Gross Margin on Product Sales

Gross margin on product sales decreased to 79% for the quarter compared to 84% in Q2 2024, primarily driven by increased royalties on AMVUTTRA.

Company Guidance

During Alnylam's Q2 2025 earnings call, the company announced robust financial performance and upwardly revised guidance. Alnylam reported $672 million in total net product revenues, marking a 64% year-over-year increase, driven by the TTR franchise's $544 million revenue, which grew by 77% year-over-year. The launch of AMVUTTRA for ATTR-CM was a significant contributor, with approximately 1,400 patients on therapy as of June 30, generating an estimated $150 million in revenue. Consequently, Alnylam raised its 2025 total net product revenues guidance from a range of $2.05 billion to $2.25 billion to a revised $2.65 billion to $2.8 billion, reflecting a $575 million increase, or 27% at the midpoint. The company also highlighted ongoing international expansions and advancements in its RNAi therapeutic pipeline, including the initiation of the TRITON-CM Phase III study for nucresiran and encouraging Phase I data for mivelsiran in Alzheimer's disease.

Alnylam Pharma Financial Statement Overview

Summary

Alnylam Pharma faces significant financial challenges with negative net profit margins, high leverage, and negative cash flows, despite a strong gross profit margin. The company's financial stability is at risk due to its high debt levels and ongoing losses.

Income Statement

Neutral

Alnylam Pharma shows a modest revenue growth rate of 4.85% in the TTM, but profitability remains a concern with negative net profit and EBIT margins. The gross profit margin is relatively strong at 58.02%, indicating efficient production, but the company struggles to convert this into net profits.

Balance Sheet

Negative

The company has a high debt-to-equity ratio of 5.18 in the TTM, indicating significant leverage, which could pose financial risks. The return on equity is negative, reflecting ongoing losses. The equity ratio is low, suggesting limited equity financing relative to total assets.

Cash Flow

Negative

Alnylam Pharma's cash flow situation is challenging, with negative operating and free cash flows. The free cash flow to net income ratio is positive, suggesting some ability to cover net losses, but overall cash flow growth is negative, indicating potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.46B	2.25B	1.83B	1.04B	844.29M	492.85M
Gross Profit	2.06B	1.92B	1.52B	868.60M	704.14M	414.80M
EBITDA	-170.93M	-178.85M	-258.24M	-926.56M	-661.56M	-736.33M
Net Income	-319.09M	-278.16M	-440.24M	-1.13B	-852.82M	-858.28M
Balance Sheet
Total Assets	4.57B	4.24B	3.83B	3.55B	3.64B	3.41B
Cash, Cash Equivalents and Short-Term Investments	2.86B	2.69B	2.44B	2.19B	2.44B	1.87B
Total Debt	1.30B	1.30B	1.31B	1.32B	997.59M	521.19M
Total Liabilities	4.32B	4.17B	4.05B	3.70B	3.06B	2.39B
Stockholders Equity	250.59M	67.09M	-220.64M	-158.22M	588.20M	1.02B
Cash Flow
Free Cash Flow	-52.09M	-42.59M	41.95M	-613.33M	-718.07M	-685.32M
Operating Cash Flow	-15.54M	-8.31M	104.16M	-541.27M	-641.69M	-614.96M
Investing Cash Flow	-110.77M	-116.84M	-336.35M	169.35M	-273.30M	-435.52M
Financing Cash Flow	231.59M	294.16M	172.13M	425.75M	1.25B	994.98M

Alnylam Pharma Technical Analysis

Technical Analysis Sentiment

Neutral

Last Price452.17

Price Trends

50DMA

409.80

Positive

100DMA

352.65

Positive

200DMA

302.19

Positive

Market Momentum

MACD

11.83

Positive

RSI

54.92

Neutral

STOCH

26.87

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALNY, the sentiment is Neutral. The current price of 452.17 is below the 20-day moving average (MA) of 456.85, above the 50-day MA of 409.80, and above the 200-day MA of 302.19, indicating a neutral trend. The MACD of 11.83 indicates Positive momentum. The RSI at 54.92 is Neutral, neither overbought nor oversold. The STOCH value of 26.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALNY.

Alnylam Pharma Risk Analysis

Alnylam Pharma disclosed 45 risk factors in its most recent earnings report. Alnylam Pharma reported the most risks in the "Legal & Regulatory" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Alnylam Pharma Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTHR	77 Outperform	18.26B	16.00	18.55%	―	17.62%	19.89%
ARGX	74 Outperform	45.20B	34.37	15.15%	―	89.58%	0.00%
RPRX	74 Outperform	20.79B	15.52	12.37%	2.43%	3.04%	53.03%
ALNY	60 Neutral	$59.21B	―	-257.82%	―	5.01%	-330.09%
SMMT	53 Neutral	13.44B	-19.09	0.00%	―	0.00%	-338.19%
BNTX	49 Neutral	23.60B	-60.81	-1.88%	―	7.51%	30.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

ALNY

Alnylam Pharma

452.17

175.84

63.63%

INCY

Incyte

86.00

19.18

28.70%

VRTX

Vertex Pharmaceuticals

387.11

-90.79

-19.00%

ARGX

Argenx Se

731.77

195.43

36.44%

GMAB

Genmab

28.04

1.56

5.89%

BNTX

BioNTech SE

96.31

-16.20

-14.40%

Alnylam Pharma Corporate Events

Executive/Board ChangesBusiness Operations and Strategy

Alnylam Pharma Appoints New Chief R&D Officer

Positive

Jun 18, 2025

On June 12, 2025, Alnylam Pharmaceuticals announced the integration of its Research and Early Development function with its Development function into a single organization, appointing Pushkal Garg as Executive Vice President, Chief Research and Development Officer. This strategic move aims to accelerate pipeline progress and foster collaboration, enhancing Alnylam’s ability to deliver RNAi therapeutics to all major tissues by 2030, thus potentially transforming patient care across a range of diseases.

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025